Recent research have centered on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopaminergic communication. While GLP agonists are commonly employed for treating type 2 diabetes, their unexpected effects on reinforcement circuits, specifically mediated by dopamine pathways, are re… Read More